These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32151507)

  • 1. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
    Lin G; Li C; Li PS; Fang WZ; Xu HP; Gong YH; Zhu ZF; Hu Y; Liang WH; Chu Q; Zhong WZ; Wu L; Wang HJ; Wang ZJ; Li ZM; Lin J; Guan YF; Xia XF; Yi X; Miao Q; Wu B; Jiang K; Zheng XB; Zhu WF; Zheng XL; Huang PS; Xiao WJ; Hu D; Zhang LF; Fan XR; Mok TSK; Huang C
    Ann Oncol; 2020 Apr; 31(4):517-524. PubMed ID: 32151507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy and influence factors analysis of EGFR TKIs on patients with lung adenosquamous carcinoma].
    Zhou SY; Hu XS; Li JL; Wang Y; Liu YT; Xing PY; Yang JL; Lin H; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):776-781. PubMed ID: 30392343
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
    Song Z; Lin B; Shao L; Zhang Y
    J Chin Med Assoc; 2013 Sep; 76(9):481-5. PubMed ID: 23769878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].
    Wang ZH; Song XY
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):90-93. PubMed ID: 28219201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients.
    Morodomi Y; Okamoto T; Takenoyama M; Takada K; Katsura M; Suzuki Y; Fujishita T; Kitahara H; Shimamatsu S; Kohno M; Tagawa T; Okano S; Taguchi K; Ichinose Y; Maehara Y
    Ann Surg Oncol; 2015 Aug; 22(8):2593-8. PubMed ID: 25373537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].
    Zhou SY; Xue Q; Ying JM; Hu XS; Yang JL; Lin H; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):50-55. PubMed ID: 30678417
    [No Abstract]   [Full Text] [Related]  

  • 11. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis.
    Wei Y; Shen K; Lv T; Wang X; Li C; Fan H; Lv Y; Liu H; Song Y
    Lung Cancer; 2018 Nov; 125():43-50. PubMed ID: 30429037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
    Iwanaga K; Sueoka-Aragane N; Nakamura T; Mori D; Kimura S
    Intern Med; 2012; 51(19):2771-4. PubMed ID: 23037472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing.
    Krause A; Roma L; Lorber T; Habicht J; Lardinois D; De Filippo MR; Prince SS; Piscuoglio S; Ng C; Bubendorf L
    Lung Cancer; 2020 Dec; 150():132-138. PubMed ID: 33137577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
    Zhou J; Song XB; He H; Zhou Y; Lu XJ; Ying BW
    Asian Pac J Cancer Prev; 2016; 17(3):965-71. PubMed ID: 27039821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
    Vassella E; Langsch S; Dettmer MS; Schlup C; Neuenschwander M; Frattini M; Gugger M; Schäfer SC
    Oncotarget; 2015 Sep; 6(27):23905-16. PubMed ID: 26068980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
    Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
    Li C; Zheng X; Li P; Wang H; Hu J; Wu L; Wang Z; Guo H; Wu F; Zhong W; Zhou C; Chu Q; Zhao J; Zheng X; Xiao W; Zhu W; Zhang L; Li Q; Jiang K; Miao Q; Wu B; Xu Y; Wu S; Wang H; Yang S; Li Y; Xia X; Yi X; Huang C; Zhu B; Lin G
    Front Immunol; 2022; 13():944812. PubMed ID: 36032124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency, clinical features and differential response to therapy of concurrent
    Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
    Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.